Curis 10-K: $(0.58) EPS, $9.4M Revenue, Warns of Insufficient Cash for 12 Months
CRIS is trading near its 52-week low of $0.671 (6.6% above the low).
Summary
CURIS INC filed its 10-K, reporting fiscal year revenue of $9.443 million and a net loss per share of $(0.58). The company's net loss improved to $(7.582) million, primarily due to a $27.189 million one-time gain on release of liability. This filing provides the full annual financial picture, following an 8-K on March 19th that reported Q4 2025 net income driven by a one-time gain. The most critical disclosure is that the company's cash was insufficient to fund operations beyond 12 months at the filing date, despite a January 2026 PIPE, making securing additional funding a key operational priority. For a micro-cap biotech, this explicit going concern warning is highly material, indicating significant financial risk and potential for further dilution. Investors will closely monitor the company's efforts to secure additional funding and the progress of its clinical programs.
At the time of this announcement, CRIS was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8M. The 52-week trading range was $0.67 to $3.13. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.